SkinBioTherapeutics plc (AIM:SBTX) announced the completion of its board investigation into the financial statements for the year ended June 30, 2025.
The company expects to publish half-year 2026 results along with restated fiscal 2025 results shortly. Trading in shares is expected to resume following the publication.
SkinBioTherapeutics appointed Saffrey LLP as independent auditor for the fiscal year ending June 30, 2026. The outgoing auditor confirmed no issues require attention.












